Dexmedetomidine: a real-world safety analysis based on FDA adverse event reporting system database.

ABSTRACT:

Objective

Using the FDA adverse event reporting system (FAERS) database to analyze the safety profile of Dexmedetomidine and provide guidance for clinical application.

Methods

Data from the FAERS database from the first quarter of 2004 to the third quarter of 2023 were collected. Reporting odds ratio (ROR), the proportional reporting ratio (PRR), and the Bayesian confidence propagation neural network (BCPNN) were employed to detect and assess adverse events associated with Dexmedetomidine.

Results

A total of 1910 reports of Dexmedetomidine as the primary suspect drug were obtained. After screening, 892 preferred terms were obtained, including 52 new preferred terms not mentioned in the drug insert. The common adverse events of Dexmedetomidine include bradycardia, card

SUBMITTER: Shuai Y 

PROVIDER: S-EPMC11377849 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature